Response: thoughtfulness required by Brigham, Greg et al.
Petry, N.M., et al., 2004. Prize reinforcement contingency management for treating cocaine users: How low can we go, and with whom? Addiction 99(3):349-360.
Petry, N.M., et al., 2005a. Vouchers versus prizes: Contingency management treatment of substance abusers in community settings. Journal of Consulting and Clinical Psychology 
73(6):1005-1014.
Petry, N.M., et al., 2005b. Effect of prize-based incentives on outcomes in stimulant abusers in outpatient psychosocial treatment programs: A National Drug Abuse Treatment Clinical  
Trials Network study. Archives of General Psychiatry 62(10):1148-1156.
Roebuck, M.C.; French, M.T.; and McLellan, A.T., 2003. DATStats: Results from 85 studies using the Drug Abuse Treatment Cost Analysis Program. Journal of Substance Abuse Treatment 
25(1):51-57. 
Sindelar, J.L., Olmstead, T.A., and Peirce, J.M., 2007. Cost-effectiveness of prize-based contingency management in methadone maintenance treatment programs. Addiction 102(9):1463-
1471.
Yates, B.T., 1999. Measuring and Improving Cost, Cost-Effectiveness, and Cost-Benefit for Substance Abuse Treatment Programs. Report for the National Institute on Drug Abuse, Division of 
Clinical and Services Research; www.drugabuse.gov/PDF/Costs.pdf.
Zarkin, G.A., and Dunlap, L.J., 1999. Implications of managed care for methadone treatment: Findings from five case studies in New York State. Journal of Substance Abuse Treatment 
17(1/2):25-36.
Zarkin, G.A.; Dunlap, L.J.; and Homsi, G., 2004. The substance abuse services cost analysis program (SASCAP): A new method for estimating drug treatment services costs. Evaluation 
and Program Planning 27(1):35-43.
RESPONSE: THOUGHTFULNESS REQUIRED
Greg Brigham, Ph.D.; Ron Jackson, M.S.W.; and Janet Wood, M.B.A., M.Ed.
Janet Wood: I found the article timely. In 
Colorado, we are trying to institute unit 
costing statewide to get folks to be able to 
define what it is they do, pair costs and out-
comes, and paint a better picture of what 
they’re delivering. Some organizations are 
very skilled in this, but not all.
Greg Brigham: I enjoyed the article. I think 
that, in general, people don’t focus enough 
on how to decide when to implement an 
evidence-based practice. I especially appreci-
ated the authors’ table of questions to ask 
prior to adopting an intervention. They are 
good questions, and they exemplify the sort 
of thoughtfulness that’s required to make 
good decisions.
 
Ron Jackson: They’re the meat of the article.
Interventions small and large
Brigham: The authors’ choice of contin-
gency management (CM) as a main example 
to illustrate cost concepts is a good one, 
in the sense that its elements are relatively 
tangible and easily counted, almost like a 
medication. You can just tally up the costs 
of the gifts and the costs of administering 
the program, and that’s basically what the 
intervention is going to cost.
Jackson: Another advantage of CM is that 
it’s relatively easy to monitor fidelity. Did 
you follow the reinforcement schedule or 
not? Did people get their reinforcers in a 
timely fashion? Yes or no?
Brigham: Cost assessment can be consider-
ably more challenging, however, for some 
other evidence-based practices. For example, 
motivational interviewing (MI), which is 
very popular, requires more training and 
supervision than CM. Fidelity evaluation 
for MI is more complex than simply count-
ing the number of gifts being given out. 
Cognitive-behavioral therapy is another 
intervention that’s more complex than CM; 
it takes more training and supervision and 
may require special staff.
Jackson: That’s right. Suppose you want to 
implement MI and integrate it routinely 
into your treatment program. You’ll use 
the basic principles described in the article 
to make your cost estimate, but it’ll be dif-
ficult to estimate how much training it’s 
going to take and how much additional 
supervision is needed to monitor and main-
tain fidelity.
Wood: CM is also simple to cost out com-
pared with many other practices, because 
you usually add it to your treatment as usual 
instead of using it to replace something else 
you do. For the same reason, the cost-benefit 
question—how much improvement am I 
getting for my investment?—is often easier 
to answer with CM.
Brigham: Yes, programs will find it difficult 
to separate out the impact of some of the big-
ger, more involved evidence-based interven-
tions from the effects of all of the associated 
inputs and changes. For those interventions, 
in general, I think programs have to rely on 
the research findings for estimates of effect 
sizes to use in their cost-benefit calculations.
Jackson: Research has fallen short, however, 
in articulating what kind of bang for the 
buck community programs can expect and 
how to measure against some benchmark. 
For example, what percentage of increase 
in positive patient outcomes can a program 
expect to get from adopting CM versus the 
cost of its treatment as usual? If I’m going 
to get a 10 percent bump in outcomes, but 
it’s going to cost me 25 percent more, I may 
not be as interested.
Brigham: Finding useful research can be a 
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estimates from studies done with treatment-
seeking people and community settings and 
providers as close as possible to its own. 
Unfortunately, many practices have been 
validated mainly in efficacy studies that were 
conducted in special settings with specialized 
counselors, narrow inclusion criteria, and 
specific control conditions, which may or 
may not resemble real care in the commu-
nity. Nevertheless, even though the estimates 
from efficacy studies may not be ideal, they 
may provide some sense of what to expect in 
the way of results, if applied thoughtfully.
Wood: The article’s references include a 
number of studies and resources that can 
help programs with cost and cost-benefit 
calculations. If you aren’t already doing cost 
accounting, you don’t have to start from the 
beginning. You can go to one of these, put 
in the specifics for your organization, and 
get the estimates you need.
A new intervention or a new  
receptionist?
Brigham: The concept of opportunity cost 
is important. If resources are limited, as 
they often are in substance abuse treatment   
settings, using a resource for one thing 
means sacrificing the opportunity to do 
something else.
There is a push now for people to adopt 
evidence-based practices, and I am a big 
supporter of this. I think it’s a really good 
idea for providers to look at these practices. 
However, programs may have other needs 
that are higher priorities for spending their 
resources. These would include, for example, 
having clean and safe facilities and making 
sure that all staff, starting with the recep-
tionist who answers the phone, treat people 
with dignity and respect. One could argue 
that having sufficient staff and adequate 
hours of operation to offer treatment on 
demand trumps the value of any interven-
tion—since failing to offer treatment in a 
timely fashion can undo what you’re try-
ing to do, and offering it quickly can really 
improve engagement and outcomes. If a 
program has a long waiting list, its lobby is 
not clean, and there aren’t enough friendly 
staff to greet people at the door, then adopt-
ing an evidence-based practice would be like 
putting an expensive GPS system into a car 
with bald tires.
Jackson: Don’t forget about the care and 
feeding of the treatment staff themselves. 
Brigham: Good point. For any intervention 
to work well, your program needs to have 
adequate salaries, benefits, and training and 
an environment that keeps people at your 
center, so that you aren’t having constant 
staff turnover.
Wood: Your basic elements of leadership, 
staff makeup, and the strength of your busi-
ness are prerequisites for putting you into a 
position to adopt evidence-based practices. 
The culture of your organization is also criti-
cal so that there is administrative support 
and an environment of acceptance of new 
ideas. I always recommend that providers 
who are just starting to explore evidence-
based practices begin with the Network for 
the Improvement of Addiction Treatment 
(www.niatx.net/Home/Home.aspx) to help 
them get used to the changes.
Jackson: One thing we haven’t talked about 
is the degree to which community treat-
ment programs routinely monitor their own 
outcomes. Those who don’t may not even 
have a baseline to compare the effect of the 
adoption of an evidence-based practice.
Wood: True. That’s step one. 
Jackson: One source of the pressure on com-
munity programs to adopt evidence-based 
practices is external mandates. A county 
contractor, a State director, a State overseer 
will say, “We want you to do more evidence-
based practice.” But you’ve only got a finite 
amount of money. They don’t tell you what 
you’re supposed to do less of.
Wood: Well, now, I’m a State director, so 
hold on here. 
Jackson: I know, Janet. But that’s the real 
world, and you know that’s true.
Wood: In Colorado we allow programs a lot 
of flexibility in what evidence-based prac-
tices they adopt. There is a wide continuum 
of interventions, with some that are easier 
and less costly to implement and others that 
require more resources and effort. At one 
end there is CM, and at the other are family 
therapies, such as multisystemic therapy, 
where you need master’s level therapists and 
2 weeks of intensive training often delivered 
out of State by the developers. In addition, 
our State uses services from the Addiction 
Technology Transfer Center (ATTC), 
provides some funds for training costs, and 
facilitates other cost-saving activities. For 
example, we sponsor semiannual research 
forums that attract about 300 people for 
raising awareness of evidence-based prac-
tices, and then we pair those events with 
actual skill-building training for a smaller 
number of people. 
That said, we are now considering 
whether we might want to choose one or 
two practices to focus on, make sure they’re 
disseminated widely, and build from there. 
The issue is the extent to which the cost of 
offering training for many different inter-
ventions diffuses our resources. We are 
constantly in touch with our ATTC , and 
we’ve got a pretty active group of people in 
recovery and other stakeholders who work 
together to help us make these decisions.
Costs to patients
Wood: The cost to patients is a real issue 
in Colorado. Our providers are not reim-
bursed for nearly the full cost of care, and 
the patients make up the difference in fees. 
The patients are bearing a high cost now, 
and new evidence-based interventions may 
push it even higher—for example, if the 
intervention requires more intensive visits 
or supplemental medications.
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concept in their paper. To me, the question 
for patients is similar to what the question 
should be for providers: What value do I 
get back for this investment?
In my experience, patients who are seri-
ous about dealing with their problems don’t 
mind incurring a lot of personal cost, even 
if they have to come to the clinic several 
times a week for several hours. What they 
don’t like to do, and shouldn’t have to do, is 
participate in things that don’t provide any 
value to them. That would include making 
extra visits just to get assessed without get-
ting treatment or having to travel to multiple 
locations. Some substance abuse treatments 
have a very high cost in time, inconvenience, 
and invasiveness, even aside from the fees.
Jackson: I completely agree. Treatment 
Center X, why are you charging me $10 
more a session now? What am I getting for 
that additional $10? Medicaid, legislatures, 
and funders ask the same questions, and you 
have to find plausible answers if you expect 
to get reimbursed.
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